ARCT (Arcturus Therapeutics Holdings) Interest Expense: $-0.01 Mil (TTM As of Mar. 2026)

What is Arcturus Therapeutics Holdings Interest Expense?

Arcturus Therapeutics Holdings ARCT -0.58% 54 Interest Expense is $-0.01 Mil as of Mar. 2026. GuruFocus rates ARCT with a GF Score™ of 54/100 and a GF Value™ of $4.41 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Arcturus Therapeutics Holdings's interest expense for the three months ended in Mar. 2026 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Arcturus Therapeutics Holdings's Operating Income for the three months ended in Mar. 2026 was $ -28.93 Mil. Arcturus Therapeutics Holdings's Interest Expense for the three months ended in Mar. 2026 was $ 0.00 Mil. GuruFocus does not calculate Arcturus Therapeutics Holdings's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Arcturus Therapeutics Holdings (NAS:ARCT) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Arcturus Therapeutics Holdings's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-28.93 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $19.68 Mil.

Arcturus Therapeutics Holdings's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate Arcturus Therapeutics Holdings's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Arcturus Therapeutics Holdings Interest Expense Historical Data

* Premium members only.

The historical data trend for Arcturus Therapeutics Holdings's Interest Expense can be seen below:

Arcturus Therapeutics Holdings Interest Expense Chart

Arcturus Therapeutics Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-2.67

-3.00

-0.77

0.00

-0.01

Arcturus Therapeutics Holdings Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															0.00	0.00	0.00	-0.01	0.00

54GF Score

Arcturus Therapeutics Holdings Inc ARCT

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Arcturus Therapeutics Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of $-0.01 Mil mean?

Arcturus Therapeutics Holdings (ARCT) has a Interest Expense of $-0.01 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Arcturus Therapeutics Holdings and its competitors.

Is Arcturus Therapeutics Holdings' Interest Expense too high?

Arcturus Therapeutics Holdings' current Interest Expense is $-0.01 Mil. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Arcturus Therapeutics Holdings' Interest Expense compare to MDWD and UNCY?

Arcturus Therapeutics Holdings' Interest Expense of $-0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Arcturus Therapeutics Holdings and its competitors. Arcturus Therapeutics Holdings's current Interest Expense is $-0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Arcturus Therapeutics Holdings stock overvalued right now?

Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.41, compared to a current price of $6.82 — trading 54.6% above its estimated fair value. The current Interest Expense is $-0.01 Mil. Arcturus Therapeutics Holdings' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current Interest Expense is $-0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued. The current stock price of $6.82 is trading 54.6% above its estimated GF Value™ of $4.41. GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.

Key valuation signals for ARCT:

Interest Expense: $-0.01 Mil
GF Value™: $4.41 vs. price of $6.82 (54.6% above fair value)
GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcturus Therapeutics Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies MDWD UNCY EQ ORMP NGEN HUMA NBP DTIL NKTX NERV VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 10285 Science Center Drive, San Diego, CA, USA, 92121

Website https://www.arcturusrx.com

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

54GF Score

Get the complete analysis for ARCT

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.82

Price

$4.41

GF Value

View ARCT Analysis

See Interest Expense data for all stocks →